Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 316 people, planned
- Started
- 23 Mar 2026
- Expected to end
- 20 Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- D.D.C dual-control technology spcetacle lenses
- Aspheric single-vision lenses
- Record updated
- 28 July 2026
Who can take part
- Age
- 8 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age between 6 and 14 years
- Cycloplegic spherical equivalent refraction between -1.50 D and -5.00 D with astigmatism ≥ -1.50 D in both eyes
- Absolute interocular difference in spherical equivalent refraction ≤ 1.50 D
- Binocular best-corrected visual acuity ≥ 1.0
- Intraocular pressure between 10 and 21 mmHg in both eyes
- Volunteer to participate in this clinical trial with signature of the informed consent form
Who cannot take part
- Participation in a drug clinical trial within 3 months or a device clinical trial within 1 month prior to enrollment
- History of eye injury or intraocular surgery or ocular trauma
- Presence of ocular diseases such as cataract, glaucoma, fundus pathology, ocular trauma, manifest strabismus, or any other condition affecting visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Participation in any myopia control clinical trial within the past 3 months and a history of myopia control interventions (e.g., orthokeratology, atropine)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meeting the inclusion criteria
- Inability to attend regular ophthalmic examinations
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The burden of myopia among Chinese children and adolescents is severe and trending toward younger ages, making control of myopia progression a public health priority. Current mainstream strategies include optical interventions, pharmacologic therapy, and environmental measures. Among these strategies, spectacle designs based on optical defocus-such as defocus-incorporated multiple-segment (DIMS) lenses-have demonstrated efficacy; however, the effect of such designs may attenuate over time because of "defocus adaptation." To address this limitation, D.D.C dual-control spectacles employ a densely staggered microlens layout, a gradient-defocus architecture, and an added peripheral "fogging zone" to disrupt the spatial distribution of defocus cues and reduce contrast, thereby delaying adaptation and enhancing myopia-control efficacy.
Read full original descriptionShow less
The present study therefore proposes a 24-month prospective randomized controlled trial in Guangzhou, enrolling eligible myopic adolescents. The trial will first compare 12-month outcomes between D.D.C-A lenses and single-vision lenses, followed by a crossover and alternating-wear phase, to systematically evaluate the safety and efficacy of the D.D.C technology in slowing myopia progression.
The 2 groups in the trial
- InterventionTreatment being tested
D.D.C dual-control technology spectacle lenses
Treatment: D.D.C dual-control technology spcetacle lenses
- ControlTreatment being tested
Aspheric single-vision spectacle lenes
Treatment: Aspheric single-vision lenses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 July 2026